Mice lacking the plasminogen activator inhibitor 1 are protected from trabecular bone loss induced by estrogen deficiency

Journal of Bone and Mineral Research

Volumn 15, Issue 8, 2000, Pages 1510-1516

  Daci, E ^a   Verstuyf, A ^a   Moermans, K ^a   Bouillon, R ^a   Carmeliet, G ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b LEGENDO   (Belgium)

Author keywords

Bone histomorphometry; Bone turnover; Mice; Ovariectomy; Plasminogen activator inhibitor 1

Indexed keywords

CALCIUM; COLLAGEN; ESTROGEN; PLASMIN; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEINASE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE ATROPHY; BONE MINERAL; BONE TURNOVER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; ESTROGEN DEFICIENCY; FEMALE; GENE; MORPHOMETRICS; MOUSE; NONHUMAN; OSTEOLYSIS; OVARIECTOMY; PROTEIN CROSS LINKING; TRABECULAR BONE;

EID: 0033915490     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.2000.15.8.1510     Document Type: Article

References (30)

1. Carmeliet P, Collen D 1995 Gene targeting and gene transfer studies of the plasminogen/plasmin system: Implications in thrombosis, hemostasis, neointima formation and atherosclerosis. FASEB J 9:934-938.
2. Allan EH, Zeheb R, Gelehrter TD, Heaton JH, Fukumoto S, Yee JA, Martin TJ 1991 Transforming growth factor beta inhibits plasminogen activator (PA) activity and stimulates production of urokinase-type PA, PA inhibitor-1 mRNA, and protein in rat osteoblast-like cells. J Cell Physiol 149:34-43.
3. Yang JN, Allan EH, Anderson GI, Martin TJ, Minkin C 1997 Plasminogen activator system in osteoclasts. J Bone Miner Res 12:761-768.
4. Fukumoto S, Allan EH, Yee JA, Gelehrter TD, Martin TJ 1992 Plasminogen activator regulation in osteoblasts: parathyroid hormone inhibition of type-1 plasminogen activator inhibitor and its mRNA. J Cell Physiol 152:346-355.
5. Hoekman K, Löwik CWGM, Van De Ruit M, Bijvoet OLM, Verheijen JH, Papapoulos SE 1991 Regulation of the production of plasminogen activators by bone resorption enhancing and inhibiting factors in three types of osteoblast-like cells. Bone Miner 14:189-204.
6. Allan EH, Martin TJ 1995 The plasminogen activator inhibitor system in bone cell function. Clin Orthop 313:54-63.
7. Mignatti P, Rifkin DB 1993 Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 73:161-195.
8. Murphy G 1995 Matrix metalloproteinases and their inhibitors. Acta Orthop Scand 66(Suppl 266):55-60.
9. Carmeliet P, Moons L, Lijnen R, Baes M, Lemaitre V, Tipping P. Drew A, Eeckhout Y, Shapiro S, Lupu F, Collen D 1997 Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet 17:439-444.
10. Daci E, Udagawa N, Martin TJ, Bouillon R, Carmeliet G 1999 The role of the plasminogen system in bone resorption in vitro. J Bone Miner Res 14:946-952.
11. Yee JA, Yan L, Dominguez JC, Allan EH, Martin TJ 1993 Plasminogen-dependent activation of latent transforming growth factor beta (TGFβ) by growing cultures of osteoblast-like cells. J Cell Physiol 157:528-534.
12. Munger JS, Harpel JG, Gleizes PE, Mazzieri R, Nunes I, Rifkin DB 1997 Latent transforming growth factor-β: Structural features and mechanisms of activation. Kidney Int 51: 1376-1382.
13. Campbell PG, Novak JF, Yanosick TB, McMaster JH 1992 Involvement of the plasmin system in dissociation of the insulin-like growth factor-binding protein complex. Endocrinology 130:1401-1412.
14. Leloup G, Delaisse JM, Vaes G 1994 Relationship of the plasminogen activator/plasmin cascade to osteoclast invasion and mineral resorption in explanted fetal metatarsal bones. J Bone Miner Res 9:891-902.
15. Leloup G, Lemoine P, Carmeliet P, Vaes G 1996 Bone resorption and response to calcium-regulating hormones in the absence of tissue or urokinase plasminogen activator or of their type 1 inhibitor. J Bone Miner Res 11:1146-1157.
16. Carmeliet P, Kieckens L, Schoonjans L, Ream B, Van Nuffelen A, Prendergast G, Cole M, Bronson R, Collen D, Mulligan RC 1993 Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization. J Clin Invest 92:2746-2755.
17. 3, KH1060. Endocrinology 136:866-872.
18. Verhaeghe J, Van Bree R, Van Herck E, Thomas H, Skottner A, Dequeker J, Mosekilde L, Einhorn TA, Bouillon R 1996 Effects of recombinant human growth hormone and insulin-like growth factor-I, with or without 17β-estradiol, on bone and mineral homeostasis of aged ovariectomized rats. J Bone Miner Res 11:1723-1735.
19. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR 1987 Bone histomorphometry: Standardization of nomenclature, symbols, and units. J Bone Miner Res 2:595-610.
20. Ammann P, Rizzoli R, Bonjour JP, Bourrin S, Meyer JM, Vassalli P, Garcia I 1997 Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency. J Clin Invest 99:1699-1703.
21. Yamamoto M, Fisher JE, Gentile M, Seedor JG, Leu CT, Rodan SB, Rodan GA 1998 The integrin ligand echistatin prevents bone loss in ovariectomized mice and rats. Endocrinology 139:1411-1419.
22. Kitazawa R, Kimble RB, Vannice JL, Kung VT, Pacifici R 1994 Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice. J Clin Invest 94:2397-2406.
23. Manolagas SC, Jilka RL 1995 Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 332:305-311.
24. Jilka RL, Takahashi K, Munshi M, Williams DC, Roberson PK, Manolagas SC 1998 Loss of estrogen upregulates osteoblastogenesis in the murine bone marrow. Evidence for autonomy from factors released during bone resorption. J Clin Invest 101:1942-1950.
25. Carmeliet P, Stassen JM, Schoonjans L, Ream B, van den Oord JJ, De Mol M, Mulligan RC, Collen D 1993 Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest 92:2756-2760.
26. Poli V, Balena R, Fattori E, Markatos A, Yamamoto M, Tanaka H, Ciliberto G, Rodan GA, Costantini F 1994 Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J 13:1189-1196.
27. Lorenzo JA, Naprta A, Rao Y, Alander C, Glaccum M, Widmer M, Gronowicz, G, Kalinowski J, Pilbeam CC 1998 Mice lacking the type I interleukin-1 receptor do not lose bone mass after ovariectomy. Endocrinology 139:3022-3025.
28. Kimble RB, Bain S, Pacifici R 1997 The functional block of TNF but not of IL-6 prevents bone loss in ovariectomized mice. J Bone Miner Res 12:935-941.
29. 3 binding to vitronectin. Nature 383:441-443.
30. Yoshitake H, Rittling SR, Denhardt DT, Noda M 1999 Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption. Proc Natl Acad Sci U S A 96:8156-8160.